Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
LPCN 2401 treatment resulted in statistically significant body composition improvement in menIncreased lean mass (LM) by 4.4% and decreased fat mass (FM) by 6.7%Reduced android fat (AF) by 4.1% and
Met primary and Hepatic Encephalopathy endpoints in Phase 2 studyIncrease in Skeletal Muscle Index observed at Week 24 was maintained through 52 weeksParticipants on placebo increased SMI when.
Company anticipates topline results from this crossover pivotal study late in the second quarter of 2024
SALT LAKE CITY, March 25, 2024 /PRNewswire/ Lipocine Inc. , a biopharmaceutical company.
Lipocine Announces Continued Commercialization Of TLANDO® Through Verity Pharmaceuticals menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.